Intravenous levetiracetam in the rat pilocarpine-induced status epilepticus model: Behavioral, physiological and histological studies

Neuropharmacology

Volumn 58, Issue 4-5, 2010, Pages 793-798

  Zheng, Yi ^a   Moussally, Jon ^a   Cash, Sydney S ^a   Karnam, Havisha B ^a   Cole, Andrew J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETIRACETAM; PILOCARPINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; BOLUS INJECTION; CONTROLLED STUDY; DOSE RESPONSE; ELECTROENCEPHALOGRAM; EPILEPTIC DISCHARGE; EPILEPTIC STATE; HIPPOCAMPUS; HISTOPATHOLOGY; LIMBIC SYSTEM; MALE; NERVE CELL LESION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; INJECTIONS, INTRAVENOUS; MALE; NEURONS; PILOCARPINE; PIRACETAM; RATS; RATS, SPRAGUE-DAWLEY; STATUS EPILEPTICUS;

EID: 77649341207     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.12.007     Document Type: Article

References (38)

1. Cavalheiro E.A., et al. Long-term effects of pilocarpine in rats: structural damage of the brain triggers kindling and spontaneous I recurrent seizures. Epilepsia 1991, 32(6):778-782.
2. Crowder K.M., et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proceedings of the National Academy of Sciences United States of America 1999, 96(26):15268-15273.
3. De Smedt T., et al. Rapid kindling in preclinical anti-epileptic drug development: the effect of levetiracetam. Epilepsy Research 2005, 67(3):109-116.
4. DeLorenzo R.J., et al. Epidemiology of status epilepticus. J Clin Neurophysiol 1995, 12(4):316-325.
5. DeLorenzo R.J., et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996, 46(4):1029-1035.
6. Doheny H.C., et al. Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. Epilepsy Research 1999, 34(2-3):161-168.
7. Fraser C.M., Sills G.J., Butler E., Thompson G.G., Lindsay K., Duncan R., Howatson A., Brodie M.J. Effects of valproate, vigabatrin and tiagabine on GABA uptake into human astrocytes cultured from fetal and adult brain tissue. Epileptic Disorders 1999, 1(3):153-157.
8. Gibbs J.E., Cock H.R. Administration of levetiracetam after prolonged status epilepticus does not protect from mitochondrial dysfunction in a rodent model. Epilepsy Research 2007, 73(2):208-212.
9. Gibbs J.E., Walker M.C., Cock H.R. Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus. Epilepsia 2006, 47(3):469-478.
10. Glien M., et al. Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia 2002, 43(4):350-357.
11. Gower A.J., et al. ucb L059, a novel anti-convulsant drug: pharmacological profile in animais. European Journal of Pharmacology 1992, 222(2-3):193-203.
12. Gower A.T., et al. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Research 1995, 22(3):207-213.
13. Hovinga C. Levetiracetam: a novel antiepileptic drug. Pharmacotherapy 2001, 21(11):1375-1388.
14. Hu R.Q., et al. Neuronal stress and injury in C57/BL mice after systemic kainic acid administration. Brain Research 1998, 810(1-2):229.
15. Husum H., et al. Levetiracetam prevents changes in levels of brain-derived neurotrophic factor and neuropeptide Y mRNA and of Y1- and Y5-like receptors in the hisocampus of rats undergoing amygdala kindling: implications for antiepileptogenic and mood-stabilizing properties. Epilepsy & Behavior 2004, 5(2):204-215.
16. Klitgaard H., et al. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. European Journal of Pharmacology 1998, 353(2-3):191-206.
17. Lamberty Y., Margineanu D.G., Klitgaard H. Absence of negative impact of levetiracetam on cognitive function and memory in normal and amygdala-kindled rats. Epilepsy & Behavior 2000, 1(5):333-342.
18. Loscher W., Honack D., Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. Journal of Pharmacology and Experimental Therapeutics 1998, 284(2):474-479.
19. Loscher W., Honack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. European Journal of Pharmacology 1993, 232(2-3):147-158.
20. Lowenstein D. Treatment options for status epilepticus. Current Opinion in Pharmacology 2005, 5(3):334-339.
21. Lynch B.A., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(26):9861-9866.
22. Margineanu D.G., Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacological Research 2000, 42(4):281-285.
23. Mayer S.A., et al. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Archives of Neurology 2002, 59(2):205-210.
24. Mazarati A.M., et al. Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus. Epilepsy Research 2004, 58(2-3):167-174.
25. Niespodziany I., Klitgaard H., Margineanu D.G. Levetiracetam inhibits the high-voltage-activated Ca2+ current in pyramidal neurones of rat hippocampal slices. Neuroscience Letters 2001, 306(1-2):5-8.
26. Oliveira A.A., et al. Evaluation of levetiracetam effects on pilocarpine-induced seizures: cholinergic muscarinic system involvement. Neuroscience Letters 2005, 385(3):184-188.
27. Patsalos P.N. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacology & Therapeutics 2000, 85(2):77.
28. Paxinos G., Watson C. The Rat Brain in Stereotactic Coordinates 1986, Academic Press, San Diego.
29. Shorvon S.D., et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000, 41(9):1179-1186.
30. Treiman D.M., Walton N.Y., Kendrick C. A progressive sequence of electroencephalographic changes during generalized convulsive status epilepticus. Epilepsy Research 1990, 5(1):49-60.
31. Turski L., et al. Review: cholinergic mechanisms and epileptogenesis. The seizures induced by pilocarpine: a novel experimental model of intractable epilepsy. Synapse 1989, 3(2):154-171.
32. Urbanska E.M., et al. NMDA-but not kainate-mediated events reduce efficacy of some antiepileptic drugs against generalized tonic-clonic seizures in mice. Epilepsia 1999, 40(11):1507-1511.
33. Walker M.C. The epidemiology and management of status epilepticus. Current Opinions in Neurology 1998, 11(2):149-154.
34. Walton N.Y., Treiman D.M. Response of status epilepticus induced by lithium and pilocarpine to treatment with diazepam. Experimental Neurology 1988, 101(2):267-275.
35. Weiss S., Cataltepe O., Cole A.J. Anatomical studies of DNA fragmentation in rat brain after systemic kainate administration. Neuroscience 1996, 74(2):541-551.
36. Wijsman J.H., et al. A new method to detect apoptosis in paraffin sections: in situ end- labeling of fragmented DNA. Journal of Histochemistry and Cytochemistry. 1993, 41(1):7-12.
37. Yan H., et al. Separation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER). Epilepsia 2005, 46(8):1170-1177.
38. Zona C., Niespodziany I., Marchetti C., Klitgaard H., Bernardi G., Margineanu D.G. Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents. Seizure 2001, 10(4):279-286.